Abstract:Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains. Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation. CAR T cell therapy has revolutionized the treatment of hematologic malignancies. Nonetheless, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success. Here we review the challenges in achieving effective CAR T cell therapy in solid tumors, and emerging CAR T cells that have shown great promise for non-small cell lung cancer (NSCLC). A growing number of clinical trials have been conducted to study the effect of CAR T cell therapy on NSCLC, targeting different types of surface antigens. They include epidermal growth factor receptor (EGFR), mesothelin (MSLN), prostate stem cell antigen (PSCA), and mucin 1 (MUC1). Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine kinase 7 (PTK7) are currently under investigation in clinical trials. The challenges in developing CAR T for NSCLC therapy and other approaches for enhancing CAR T efficacy are discussed. Finally, we provide our perspective on imaging CAR T cell action by reviewing the two main radionuclide-based CAR T cell imaging techniques, the direct labeling of CAR T cells or indirect labeling via a reporter gene.

The Landscape of Cell and Gene Therapies for Solid Tumors

Gene therapy in solid tumors: trends in trials in China and beyond

Genetically engineered T cells for cancer immunotherapy

Section Review—Oncologic, Endocrine & Metabolic: Gene Therapy Strategies for Cancer

Advanced gene therapy system for the treatment of solid tumour: A review

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors

Advancement and prospects of tumor gene therapy

Advances in tumor immunotherapy and gene therapy

Advance in Gene Therapy of Tumors

Clinical development of mRNA therapies against solid tumors

Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review

Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Gene Therapy for Lung Cancer

Current Progress in CAR-T Cell Therapy for Solid Tumors

Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors

Future Trends in CAR-T Cellular Immunotherapy and the Pros and Cons in Cancer Treatment

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

Bright future or blind alley? CAR-T cell therapy for solid tumors